Abstract. The cytotoxic effect of trastuzumab in combination with oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2 (HER2)-overexpressing human pancreatic cancer cell line TRG in vitro and in vivo was investigated. HER2 expression in TRG was analyzed by RT-PCR and flow cytometry. For in vitro experiments, 5-fluorouracil (5-FU) was used instead of S-1. In vivo studies were conducted with TRG xenografts in athymic mice. Trastuzumab (10 mg/kg) was administered intraperitoneally once a week for 4 weeks. S-1 (10 mg/kg) was administered orally 5 days a week for 4 weeks. The results showed that TRG cells were positive for HER2 mRNA and overexpressed HER2 protein. Either trastuzumab or 5-FU concentration-dependently inhibited the growth of TRG cells. The combination of trastuzumab and 5-FU resulted in a significant inhibition of growth of TRG cells compared to either agent alone (P<0.001). Incubation of TRG cells with peripheral blood mononuclear cells after treatment with trastuzumab enhanced the antiproliferative effect of trastuzumab, which could be the result of antibodydependent cellular cytotoxicity. The combination of trastuzumab and S-1 resulted in a significant reduction in xenograft volume compared to each agent alone (P<0.0001).
Introduction
HER2 (human epidermal growth factor receptor 2) is a transmembrane tyrosine kinase receptor, which regulates cell growth and differentiation. A ligand binds to HER2 receptor, and HER2 forms a heterodimer with other receptors of the HER family (HER1, HER3, HER4), causing it to mediate signaling to cancer cells to proliferate. HER2 is overexpressed in 25-30% of breast cancers and is associated with poor prognosis for breast cancer patients (1) (2) (3) . The anti-HER2 antibody trastuzumab (Herceptin) inhibits tumor growth in HER2-overexpressing breast cancer (4) , and the response rate of trastuzumab alone for HER2-overexpressing breast cancer patients is 15-26% (5, 6) . Since the mechanism of action of trastuzumab is different from that of traditional chemotherapeutic agents, trastuzumab is expected to enhance the antitumor effect of chemotherapeutic agents without increasing their toxicity. Therefore, various combinations of trastuzumab and chemotherapies have been tried for breast cancer patients (7, 8) . In pancreatic cancer, HER2 is overexpressed in 17-45% of the patients (9) (10) (11) (12) (13) . However, the efficacy of trastuzumab as a single agent or in combination with chemotherapy for pancreatic cancer patients has not been fully evaluated. In a phase II study of gemcitabine and trastuzumab for pancreatic cancer patients, the response rate of trastuzumab and gemcitabine was similar to gemcitabine alone (14) .
S-1 is an oral preparation of 5-fluorouracil (5-FU) consisting of tegafur (a prodrug of 5-fluorouracil), 5-chloro-2,4-dihydroxypyridine, which inhibits the degradation of 5-fluorouracil, and potassium oxonate, which reduces gastrointestinal toxicity. Hayashi et al (15) reported that the response rates of S-1 alone and the combination of S-1 and cisplatin for pancreatic cancer patients were 20.0 and 57.1%, respectively.
In this study, we investigated the antitumor activity of trastuzumab and S-1 in HER2-overexpressing human pancreatic cancer in vitro and in vivo.
Materials and methods
Compounds. Trastuzumab (Genentech, Inc., San Francisco, CA) was provided by Chugai Pharmaceutical (Tokyo, Japan). PCR amplifications were carried out in a T-Personal thermal cycler (Biometra, Göttingen, Germany) with Plattinum Taq DNA polymerase (Invitrogen Corp.). The following primers were used: HER1, forward (5' CCT GAG CTC TCT GAG TGC AAC C 3') and reverse (5' AGA TAC TCG GGG TTG CCC ACT G 3'); HER2, forward (5' CGG GAG ATC CCT GAC CTG CTG GAA 3') and reverse (5' CTG CTG GGG TAC CAG ATA CTC CTC 3'); HER3, forward (5' TGG GGA GTC TTG CCA GGA GTC 3') and reverse (5' GAG GAG GGA GTA CCT TTG AG 3'); and HER4, forward (5' CCT CTC CTT CCT GCG GTC TGT 3') and reverse (5' AAG TCT GGC AAT GAT TTT CTG TGG G 3') (16) . Thermal cycling conditions for HER1, HER2 and HER3 were as follows: denaturation at 94˚C for 30 sec; annealing at 60˚C for 30 sec; and extension at 72˚C for 1 min for 28 cycles. For HER4, the same conditions were used except that the PCR annealing temperature was 55˚C. An additional PCR amplification directed at the glucose-6-phosphate dehydrogenase (G6PDH) gene was performed as a control using primers forward (5' CTG ACC TAC GGC AAC AGA TA3') and reverse ( 
Effect of trastuzumab and 5-fluorouracil on proliferation of human pancreatic cancer cells in vitro. TRG cells (1x10
4 ) were seeded in each well of a BD Falcon 96-well microplate (Becton Dickinson Labware). Cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum. After a 1-day incubation at 37˚C in a 5% CO 2 incubator, various concentrations of trastuzumab (0, 0.1, 1, 10 and 100 μg/ml) or 5-fluorouracil (0, 1, 10, 100 and 1000 ng/ml) were added. After 3 days of incubation at 37˚C in a 5% CO 2 incubator, the proliferation of the cells was measured by MTT [3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay.
Effect of combinations of trastuzumab and 5-fluorouracil on human pancreatic cancer cells in vitro.
After a 1-day incubation of 5x10 5 TRG cells seeded in a 10-cm dish with 5 ml 10% fetal bovine serum at 37˚C in a 5% CO 2 incubator, trastuzumab and 5-fluorouracil were added as single agents and in combination. No agent was added to the control. After 3 days of incubation at 37˚C in a 5% CO 2 incubator, cells were harvested by trypsinization and were counted. Experiments were performed in triplicate. Percentages of control cell proliferation (cell number/mean cell number in controls x 100) were compared in each group.
Antibody-dependent cellular cytotoxicity (ADCC) of trastuzumab on human pancreatic cancer cells in vitro.
After a 1-day incubation of 1x10 6 TRG cells in 5 ml 10% fetal bovine serum at 37˚C in a 5% CO 2 incubator, trastuzumab and 5-fluorouracil were added as single agents and in combination. No agent was added to the control. After 2 days of incubation at 37˚C in a 5% CO 2 incubator, cells were washed to remove the added agent. In order to analyze antibody-dependent cellular cytotoxicity (ADCC) with trastuzumab, 1x10 7 peripheral blood mononuclear cells (PBMCs) were added to each group. After 12 h of incubation at 37˚C in a 5% CO 2 incubator, cells were counted. Experiments were performed in triplicate. Percentages of control cell proliferation were compared in each group.
Effect on human pancreatic cancer xenografts of a combination of trastuzumab and S-1.
The in vivo effects of trastuzumab and S-1 as single agents and in combination were tested in a human pancreatic cancer xenograft model in athymic mice. The viable TRG cells (5x10 6 ) were injected subcutaneously into the mediodorsal regions of athymic mice. After a week of subcutaneous tumor growth, the mice were randomized into three treatment groups and a control group of 10 mice each, and the treatment was started. Trastuzumab was given intraperitoneally once a week for 4 weeks at a dose of 10 mg/kg. S-1 was given orally 5 days a week for 4 weeks at a dose of 10 mg/kg. The control group received no treatment. Tumor size and body weight were measured once a week, and tumor volume was calculated by the formula 1/2 x large diameter x (small diameter) 2 .
Statistical analysis. Results were expressed as the means ± SE. Statistical significance was determined by the Student's ttest in comparing treatment groups. A P value <0.05 was accepted as statistically significant.
Results

HER1 (EGFR), HER2, HER3, and HER4 RNA expression in TRG cells analyzed by RT-PCR.
The mRNA expression of HER1, HER2, HER3, and HER4 was analyzed by RT-PCR. TRG cells were positive for HER1, HER2, and HER3, but not for HER4 (Fig. 1) . level analyzed by flow cytometry. TRG cells overexpressed HER2 protein in flow cytometric analysis (Fig. 2) . Although the HER2 level of TRG cells did not change after treatment with trastuzumab alone, the HER2 level was increased after treatment with 5-fluorouracil alone and with a combination of trastuzumab and 5-fluorouracil (Fig. 3) .
Expression level of HER2 protein in TRG cells
Effect of trastuzumab and 5-fluorouracil on proliferation of human pancreatic cancer cells in vitro.
TRG cells were cultured in the presence of 0.1, 1, 10, and 100 μg/ml trastuzumab or 1, 10, 100, and 1000 ng/ml 5-fluorouracil. After 4 days of incubation, MTT assay was performed. Either trastuzumab or 5-fluorouracil concentration-dependently inhibited the growth of TRG cells (Fig. 4) .
Effect of a combination of trastuzumab and 5-fluorouracil on human pancreatic cancer cells in vitro.
TRG cells were cultured in the presence of 1 μg/ml trastuzumab and 10 ng/ml 5-fluorouracil alone and in combination, and the growth inhibition effects were compared. The combination of trastuzumab and 5-fluorouracil resulted in significant inhibition of the growth of TRG cells compared to either agent alone (P=0.0004 vs. 5-fluorouracil alone, P=0.0006 vs. trastuzumab alone) (Fig. 5) .
Antibody-dependent cellular cytotoxicity (ADCC) of trastuzumab on human pancreatic cancer cells in vitro.
After incubation of TRG cells with trastuzumab and 5-fluorouracil, PBMCs were added to the TRG cells and the growth inhibition effects were compared. The inhibition effect of the trastuzumab group (P=0.001) and 5-fluorouracil group (P=0.009) in the presence of PBMSc was enhanced compared to that without PBMCs (Fig. 5) . Although the inhibition effect in the trastuzumab group and the 5-fluorouracil group was not significantly different when PBMCs were not added, the inhibition effect in the trastuzumab group was greater than in the 5-fluorouracil group (P=0.06) in the presence of PBMCs. In the combination group, the enhancing effect on growth inhibition induced by PBMCs was not observed.
Effect of the combination of trastuzumab and S-1 on human pancreatic cancer xenografts.
The in vivo effects of trastuzumab and S-1 alone and in combination were tested in a TRG subcutaneous xenograft model in athymic mice. Trastuzumab was given intraperitoneally once a week for 4 weeks at a dose of 10 mg/kg. S-1 was given orally 5 times a week for 4 weeks at a dose of 10 mg/kg. Two mice in the control group that received no treatment died within 4 weeks. The tumor volumes at 4 weeks in the three treatment groups were significantly reduced as compared with the control group (P<0.01) (Fig. 6 ). The combination of trastuzumab and S-1 resulted in a significant reduction (P<0.0001) in tumor volume compared to either agent alone. Weight loss in the combination group was significantly less than in the control group (P=0.0004) and the S-1 group (P<0.0001), which demonstrated that the combination of trastuzumab and S-1 probably did not increase toxicity (Fig. 7) .
Discussion
Although chemotherapy for pancreatic cancer patients has not been established, Hayashi et al (15) recently reported that the response rates of S-1 alone and the combination of S-1 and cisplatin for pancreatic cancer patients were 20.0 and 57.1%, respectively. Therefore S-1 is one of the hopeful drugs for pancreatic cancer patients. S-1 is an oral preparation of 5 (17) . However, the activity of TS and DPD was not evaluated in this study. HER2 is overexpressed in 17-45% of pancreatic cancer patients (9-13). TRG cells expressed HER1, HER2, and HER3 mRNA in RT-PCR and overexpressed HER2 protein in flow cytometry. HER2 forms heterodimers with other members of the HER family to stimulate intercellular signaling pathways. In pancreatic cancer tissue, HER-2 coexpression with HER-3 and HER-4 is frequently seen (18) . Treatment of TRG cells with trastuzumab resulted in concentration-dependent growth inhibition in vitro. An antitumor effect of trastuzumab for TRG xenografts was also observed. HER2 down-regulation is one possible mechanism of the antitumor effect of trastuzumab, which has not yet been completely elucidated (19, 20) . The binding of trastuzumab to HER2 proteins decreases expression of cell surface HER2, thereby weakening growth signaling and inhibiting cell proliferation. In this study, we analyzed the change in HER2 expression level after treatment of TRG cells with trastuzumab, but HER2 down-regulation was not observed. Therefore the action of trastuzumab against TRG cells was likely due to the prevention of dimer formation, initiation of G1 arrest and induction of p27, or prevention of HER2 cleavage (21) , although further research is needed to explore these possibilities. Trastuzumab possesses the Fc domain of human IgG1, indicating that trastuzumab induces antibodydependent cellular cytotoxicity (ADCC), and inhibits cell growth (4), in addition to direct antitumor activity as previously described. In order to determine the ADCC induced by trastuzumab against TRG cells in vitro, we added peripheral blood mononuclear cells (PBMCs) to TRG cells after treatment with trastuzumab and 5-fluorouracil and analyzed cell growth inhibition. The growth inhibition in 5-fluorouracil was increased by PBMCs as well as in trastuzumab. The enhanced growth inhibition in 5-fluorouracil, which is not an antibody-induced agent, seemed to be due to a direct cytotoxic effect of PBMCs. The enhanced effect by PBMCs in trastuzumab was greater than in 5-fluorouracil suggesting that ADCC could be operative in trastuzumab. In the combination group, the enhanced effect by PBMCs was not observed, since the cytotoxic effect of the combination of trastuzumab and 5-fluorouracil was too strong.
Previous studies have demonstrated synergistic or additive interactions between trastuzumab and a variety of chemotherapeutic drugs, such as paclitaxel, doxorubicin, and cisplatin (22) (23) (24) (25) , but few studies have reported the effect of trastuzumab with 5-fluorouracil. Pegram et al (25) reported that in an in vitro study using breast cancer cell line SK-BR-3, trastuzumab exhibited an antagonistic interaction against 5-fluorouracil explained by the decreased effect with trastuzumab in the percentage of cells in the S phase, where 5-fluorouracil exerts cytotoxic effects. Fujimoto-Ouchi et al (26) reported that the combination of trastuzumab and the oral fluoropyrimidine capecitabine demonstrated additive antiproliferative activity in human breast cancer KPL-4 and BT-474 xenograft models, even though in vitro treatment with trastuzumab and 5-fluorouracil showed antagonistic antiproliferative activity in these cell lines. They suggested that this discrepancy between the in vivo and in vitro experiments could be due to ADCC induced by trastuzumab. In the present in vitro experiment, the enhanced effect of the combination of trastuzumab and 5-fluorouracil in the TRG cells was observed even without PBMCs, demonstrating that ADCC may not participate in the enhanced effect. Furthermore, the combination of S-1 and trastuzumab in in vivo experiments with TRG cells resulted in additive interactions.
One mechanism which may explain this enhanced effect of the combination of trastuzumab and 5-fluorouracil is upregulation induced by chemotherapeutic agents. Previous research has demonstrated that exposure of several cancer cell lines to doxorubicin resulted in an increase in expression of the EGFR (27) . This phenomenon has been proposed to explain the synergistic cytotoxic effects of doxorubicin used in combination with anti-EGFR monoclonal antibodies. On the other hand, Pegram et al (25) reported that following exposure to doxorubicin, HER2 expression levels in SK-BR-3 breast carcinoma cells were unaltered. Treatment of TRG cells with 5-fluorouracil alone and the combination of 5-fluorouracil and trastuzumab resulted in an increase in HER2 expression. These data suggest that the enhanced effect with the combination of trastuzumab and 5-fluorouracil could be due to increased sensitivity for trastuzumab in TRG cells resulting from HER2 up-regulation. However, the interaction with trastuzumab and chemotherapeutic agents remains to be elucidated, and further research is needed to explore these effects.
In conclusion, we demonstrated the additive interaction with the combination of trastuzumab and 5-fluorouracil in vitro and the additive interaction with the combination of trastuzumab and S-1 in vivo using a HER2-overexpressing human pancreatic cell line. These data indicate that the clinical efficacy of the combination of trastuzumab and S-1 against HER2-overexpressing pancreatic cancer is worth investigating. Figure 6 . The in vivo effects of trastuzumab and S-1 as single agents and in combination were tested in a TRG subcutaneous xenograft model in athymic mice. Trastuzumab was given intraperitoneally once a week for 4 weeks at a dose of 10 mg/kg. S-1 was given orally 5 times a week for 4 weeks at a dose of 10 mg/ kg. The tumor volumes at 4 weeks in the three treatment groups were significantly reduced as compared with the control group (P<0.01). The combination of trastuzumab and S-1 resulted in a significant reduction (P<0.0001) in tumor volume compared to either agent alone. Figure 7 . The body weight changes in mice treated with trastuzumab and S-1 as single agents and in combination. Body weight loss in the combination group was significantly less than in the control group (P=0.0004) and the S-1 group (P<0.0001) demonstrating that the combination of trastuzumab and S-1 probably did not increase toxicity.
